Proactive: Race Oncology receives positive results from AML trial of Bisantrene
Race CEO Dr Daniel Tillett speaks with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML).
Read the article here, and watch the full interview below.